Dialectically Viewing the Status of Adverse Drug Reaction Monitoring and Evaluation in China

Abstract

Abstract: Objective To explore the status of ADR monitoring and evaluation in China, which could provide references for holding the future trend of this work scientifically. Methods The internal relation of the factors between the achievements and problems, agencies and teams, the quantity and quality of the report, the hospital reporting and the enterprise reporting, monitoring and reevaluation, sentinel surveillance and wide coverage, and all that were analyzed by using the method of dialectical analysis, which were hackled by affirming the achievements and identifying problems. Results and Conclusion It is essential to clarify the vague understanding, to clear direction, and to enhance the sense of pride, responsibility and professional self-identity for ADR monitoring.

Key words: adverse drug reaction(ADR), monitoring, evaluation

CLC Number:

R95
R994.11

LI Wen-wu . Dialectically Viewing the Status of Adverse Drug Reaction Monitoring and Evaluation in China [J]. Chinese Journal of Pharmacovigilance, 2013, 10(6): 337-340.

References

[1] 沈璐,刘巍,范燕,等. 论我国药品不良反应监测技术工作的发展阶段[J]. 中国药物警戒,2012,9(3)：146-149.
[2] CFDA.中华人民共和国药品管理法[EB/OL]. 2001-12-01. http://www.sda.gov.cn/WS01/CL0784/ 23396.html.
[3] CFDA.中华人民共和国药品管理法实施条例[EB/OL]. 2002-09-15. http://www.sda.gov.cn/WS01/CL0784/23395.html.
[4] CFDA.药品不良反应报告和监测管理办法[EB/OL]. 2011-07-01.http://www.sda.gov.cn /WS01 /CL0053/62621.html.
[5] CFDA.药品注册管理办法[EB/OL]. 2007-10-01. http://www.sda.gov.cn/WS01/CL0053/24529.html.
[6] CFDA.药物临床试验质量管理规范[EB/OL].2003-09-01.http://www.sda.gov.cn/WS01/CL0053/ 24473.html.
[7] CFDA.药品生产质量管理规范[EB/OL]. 2011-03-01. http://www.sda.gov.cn/WS01/CL0053/ 58500.html.
[8] CFDA.关于印发《药品经营质量管理规范认证管理办法》的通知[EB/OL].2003-04-24.http://www.sda.gov.cn/WS01/CL0058/9340.html.
[9] 中华人民共和国国家卫生和计划生育委员会.卫生部国家中医药管理局总后勤部卫生部关于印发《医疗机构药事管理规定》的通知[EB/OL].2011-01-30.http://www.moh.gov.cn/mohyzs/s3585/201103/51113.shtml.
[10] CFDA.2011年国家药品不良反应监测年度报告[EB/OL].2012-05-13.http://www.sda.gov.cn/WS01/CL0078/72193.html.
[11] Sten Olsson.Vigibase now over 7 million.UPPSALA REPORTS.January 2012(56):4.
[12] CFDA.关于加强药品不良反应监测体系建设的指导意见[EB/OL].2011-11-09.http://www.sda.gov.cn/WS01/CL0844/66936.html.
[13] 中华人民共和国国家卫生和计划生育委员会.中华人民共和国执业医师法[EB/OL]. 1999-05-01. http://www.moh.gov.cn/zwgkzt/pfl/200804/18250.shtml.
[14] 李文武,刘超,李学林,等.浅谈我国药品不良反应监测自愿报告
系统[J]. 药物流行病学杂志, 2010,19(1):50-52.

[1]	JIA Yinyin, ZHANG Caishu, ZHOU Ying, LIU Li, GENG Ying, WEI Ningyi, NIU Sijing, CHEN Hua, XU Hui. Evaluation methods for aerodynamic particle size distribution of fine particles in inhaled products [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 141-146.
[2]	JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166.
[3]	ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie. Adverse reaction monitoring of toothpaste in China under the new regulatory system [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222.
[4]	GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe. Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5.
[5]	FANG Zhie, LI Chengxian, BAI Zhaofang, ZHAO Xu, WANG Jiabo, XIAO Xiaohe. Investigation of objectivity in the relationship between aristolochic acid and hepatocellular carcinoma [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 20-24.
[6]	ZHANG Qi, CHEN Min, ZHANG Shiqing. Conditional approval of medical devices in the United States and enlightenment [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1007-1010.
[7]	TAI Jun, YU Miao, ZHANG Lin, LEI Yi, LIU Junting, LI Tao, HUANG Guimin, CHENG Yijing, NIE Xiaolu, WANG Qing. Active monitoring of adverse reactions related to haemocoagulase agkistrodon for injection in children [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1011-1016.
[8]	HUO Yanfei, TIAN Yuejie, XU Lili, XIE Yanjun, CHANG Hong, SUN Chunxiao, LI Xia. 535 reports of new and serious adverse drug reactions caused by preparations of lappaconitine hydrobromide [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 921-926.
[9]	HUANG Cuili, GAO Ao, WANG Jiaxi, GUO Haili, XU Xiaohan, CHENG Yinchu, GUO Daihong. Automatic monitoring and assessment of antibiotics-related thrombocytopenia [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 807-811.
[10]	CHEN Jie, QIN Kan. Evaluation of individualized parenteral nutrition delivery [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 812-816.
[11]	LIU Yuanxi, GU Donglin, WANG Qi, YAO Lingwen, WANG Ying, JIN Hongyu, MA Shuangcheng. Determination of 87 types of pesticide residues in Polygoni Multiflori Radix by LC-MS/MS [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 601-608.
[12]	NIE Xiaolu, TANG Shaowen, YU Jinyang, SONG Haibo, FU Zhu, SUN Feng. Interpretations of reporting recommendations intended for pharmaceutical risk minimization evaluation studies(RIMES) statement [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 524-529.
[13]	YUE Xiaolin, LU Song, ZHANG Lan. Research in the construction of comprehensive evaluation systems of drugs in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 530-535.
[14]	LIU Huan, YUAN Hui, YIN Jingjing, LIU Mengya, QIN Xiujun, LI Jianguo. General toxicology of Yiya Jianpi jel among juvenile animals [J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 416-422.
[15]	ZHAO Yan, LIU Wenbo, ZHAO Yifei, LI Dong, ZHENG Lijia, SONG Yana, ZHAO Yujuan, DONG Fang. Applicability of patient registry research to regulation of medical devices [J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 423-427.